These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 33682725)

  • 1. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study.
    Sun X; Dou K; Xue L; Xie Y; Yang Y; Xie A
    Clin Transl Sci; 2024 Jan; 17(1):e13720. PubMed ID: 38266062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers.
    Pachi I; Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Stamelou M; Trapali XG; Papageorgiou SG; Stefanis L
    Parkinsonism Relat Disord; 2021 Oct; 91():1-8. PubMed ID: 34425330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
    Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
    J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
    Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
    J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neurofilament light chain in LRRK2 related Parkinson's disease: A five years follow-up.
    Nabizadeh F; Mohamadzadeh O; Hosseini H; Rasouli K; Afyouni NE
    J Clin Neurosci; 2023 Apr; 110():12-18. PubMed ID: 36780781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2-associated Parkinson's disease patients have better stereopsis than idiopathic Parkinson disease.
    Sun L; Chan P
    Clin Neurol Neurosurg; 2018 Jun; 169():174-177. PubMed ID: 29705653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
    Ahamadi M; Mehrotra N; Hanan N; Lai Yee K; Gheyas F; Anton J; Bani M; Boroojerdi B; Smit H; Weidemann J; Macha S; Thuillier V; Chen C; Yang M; Williams-Gray CH; Stebbins GT; Pagano G; Hang Y; Marek K; Venuto CS; Javidnia M; Dexter D; Pedata A; Stafford B; Akalu M; Stephenson D; Romero K; Sinha V;
    Clin Pharmacol Ther; 2021 Aug; 110(2):508-518. PubMed ID: 33894056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
    Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
    JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.
    Ben Sassi S; Nabli F; Hentati E; Nahdi H; Trabelsi M; Ben Ayed H; Amouri R; Duda JE; Farrer MJ; Hentati F
    Parkinsonism Relat Disord; 2012 Mar; 18(3):243-6. PubMed ID: 22056842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
    Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
    Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study.
    Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Pachi I; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2020; 10(2):481-487. PubMed ID: 32176655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucocerebrosidase mutations and uric acid levels in Parkinson's disease: A 3-years investigation of a potential biomarker".
    Mozafar M; Kazemian S; Hoseini E; Mohammadi M; Alimoghadam R; Shafie M; Mayeli M;
    Clin Park Relat Disord; 2023; 8():100177. PubMed ID: 36590455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
    Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
    Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.